The morbidity and mortality of liver cirrhosis have been increasing in recent years, and it has been ranked as the 14th most common cause of death worldwide and the 4th in Central Europe. Tsochatzis et al. from the United Kingdom reviewed recent research on cirrhosis, looking at it as a dynamic process and summarizing its clinical stages and strategies for the management of important complications, and published a review in the January 27, 2014 issue of The Lancet. Nowadays, cirrhosis should be viewed not only as a single end-stage disease, but as a group of systemic diseases that can be staged according to significant clinical symptoms. Cirrhosis can be seen as a dynamic evolutionary process and is mainly classified according to the prognosis as follows: stage 1: in the compensated stage, before the development of esophageal varices, with a one-year mortality rate of about 1%; stage 2: still in the compensated stage, but with the development of esophageal varices, with a one-year mortality rate of 3-4%; stage 3: decompensated stage, with the development of ascites, with a one-year mortality rate of 20%; stage 4: decompensated stage, with esophagogastric fundic varices Stage 5: severe decompensation with infection and renal dysfunction, with a one-year mortality rate of 67%. In the diagnosis of liver cirrhosis, the diagnostic model of liver fibrosis established by combining various serum indicators has become a hot spot for research in recent years. Among a series of non-invasive diagnostic indexes of liver fibrosis proposed at home and abroad, the more representative ones are Fibro Test (FT), Forns Index, APRI Index and Hepascore. They must also be combined with ultrasound, CT, MRI and acoustic radiation force pulsed imaging techniques to provide a comprehensive assessment of the disease in patients with liver cirrhosis. In contrast to the previous traditional pathological classification, a new assessment method has been recently introduced, namely the quantitative assessment of liver fibrosis in combination with collagen area ratio (CPA), which is closely related to hepatic venous pressure gradient (HVPG) and clinical outcome prediction.